0 Items
Select Page

Streptococcus pneumoniae

Streptococcus pneumoniae is a major cause of morbidity and mortality, globally causing more deaths than any other infectious disease. At highest risk are the smallest children and elderly, with approximately one million children below 5 years of age dying, annually (CDC). Pneumococcal diseases range from mild respiratory tract mucosal infections, such as sinusitis, to more severe diseases such as pneumonia, septicaemia and meningitis.

The Native Antigen Company are committed to supporting research into Streptococcus, offering specific monoclonal antibodies to this bacterium.

Streptococcus Background

Streptococcus pneumoniae is a lancet-shaped, gram-positive, facultative anaerobic bacterium. In humans, S. pneumoniae primarily colonizes the nasopharynx and transmission occurs from person-to-person via respiratory secretions from patients infected wit, S. pneumoniae, and from healthy carriers. In susceptible individuals, the bacteria can spread to the lower respiratory tract, the inner ear or sinuses, to cause a range of illnesses, referred to as pneumococcal disease.

Worldwide, S. pneumoniae is the major cause of pneumonia, sepsis, and meningitis and the leading cause of community-acquired pneumonia in young children and the elderly.

Streptococcus pneumoniae Antibodies

The Native Antigen Company are pleased to offer a pair of monoclonal antibodies that are specific to Streptococcus pneumoniae, which are suitable for use in the development of immunoassays.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Why Zika virus’s cross-reactivity with Dengue might be hampering your research

Given the impact of Zika, it’s no surprise that a global contingent of epidemiologists, academic researchers, and pharmaceutical companies are striving to develop effective disease control measures and treatments. One challenge currently hindering the...

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

6 + 7 =

Live Customer Feedback